GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Earnings Yield (Joel Greenblatt) %

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Earnings Yield (Joel Greenblatt) %

: 5,000.00% (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

Cyclacel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-0.51 Mil. Cyclacel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.45 Mil. Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 5,000.00%.

The historical rank and industry rank for Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

CYCC' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5486.61   Med: 110.61   Max: 25267.93
Current: 2500

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Cyclacel Pharmaceuticals was 25267.93%. The lowest was -5486.61%. And the median was 110.61%.

CYCC's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -15.465 vs CYCC: 2500.00

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cyclacel Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Cyclacel Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,111.11 -64.52 -1,000.00 277.78 5,000.00

Cyclacel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.78 666.67 1,111.11 2,000.00 5,000.00

Competitive Comparison

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.



Cyclacel Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Cyclacel Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-25.453/-0.5137637
=4,954.22 %

Cyclacel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.45 Mil.



Cyclacel Pharmaceuticals  (NAS:CYCC) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Cyclacel Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Headlines